BGB-A317 shows activity in multiple cancer types
WALTHAM, Mass.—Clinical-stage biopharmaceutical company BeiGene Ltd. presented updated clinical data on its ongoing Phase 1 study of BGB-A317 in patients with advanced solid tumors at last month’s Society for Immunotherapy of Cancer 31st Annual Meeting. The drug is an investigational humanized monoclonal antibody against PD-1 and is being evaluated in a multicenter, open-label trial to determine its safety, tolerability, pharmacokinetics and antitumor activity in patients with advanced solid tumors. Of the 99 evaluable patients, there were 15 confirmed partial responses across nine cancer types and 23 cases of stable disease.
“We continue to see promising antitumor activity with BGB-A317 and a safety profile that is consistent with this class of molecules,” said Dr. Jayesh Desai, a medical oncologist at The Royal Melbourne Hospital and Peter MacCallum Cancer Centre in Melbourne, Australia, and coordinating principal investigator of the study.